ADMA Biologics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2021
January 19, 2022 at 07:01 pm IST
ADMA Biologics, Inc. provided revenue guidance for the fourth quarter and full year of 2021. The company expects record fourth quarter 2021 revenues of approximately $26 million, compared to $14 million during the fourth quarter of 2020, reflecting an approximate 86% increase.
For full year 2021, the company expects total revenues of approximately $81 million, compared to $42 million for the full year 2020, reflect a substantial increase of approximately 92% over full year 2020.